NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that the U.S. Food and Drug…Original Article
Chiasma Announces FDA Acceptance of Mycapssa New Drug Application Resubmission
